VivoSeq
Oncology

Bone Giant Cell Tumor

2

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Bone Giant Cell Tumor is an early-stage landscape with 2 programs across 1 company. The most active players are Amgen. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical1

Denosumab

Amgen

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Indocyanine Green

CHX Technologies Inc.

Analysis

Modality Breakdown

2programs
Small molecule150%
Monoclonal antibody150%

Modality classified for 100% of 2 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)